Register for our free email digests:
Division of Teva Pharmaceutical Industries Ltd.
Latest From Tesaro Inc.
After one year of testing the waters, China’s Drug Marketing Authorization Holder system is likely to have an earlier than expected start to the launch of final law amendment procedures, since the pilot scheme has significantly reduced investment duplication and encouraged pharma companies to file more innovative drug applications.
Public biopharma offerings gained momentum, including four IPOs during the last week of June, as US investors looked kindly on the sector ahead of July 4 celebrations. Also, VC investment continued unabated as Atlas Venture closed a new $350m fund.
Clovis Oncology is forging ahead with a filing for a maintenance indication for its PARP inhibitor Rubraca in a broad ovarian cancer population as new data from ARIEL3 blow the field wide open.
R&D-based big pharma groups in China with sufficient cash flow are increasing their strategic investments in overseas companies and products with an eye on entry to the global market, while start-ups continue to actively raise new funds from venture capitalists.
- Therapeutic Areas
- Gensia Sicor Inc.
- North America
- Parent & Subsidiaries
- Teva Pharmaceutical Industries Ltd.
- Senior Management
Marvin Samson, Pres. & CEO
Michael D Cannon, EVP, CSO
Kenneth Lomartire, VP, R&D
Alan Goldschein, VP, Sales & Mktg.
- Contact Info
Phone: (949) 455-4700
Irvine, CA 92618-1909
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.